Skip to content

Impact of the Covid-19 on RSV

Impact of the Covid-19 Pandemic on the Epidemiology of Respiratory Syncytial Virus

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05348616
Acronym
IPCoVRS-2
Enrollment
600
Registered
2022-04-27
Start date
2022-05-31
Completion date
2025-07-01
Last updated
2022-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinovirus, RSV Infection

Keywords

RSV epidemic, Covid-19 RSV interaction, Children, Non-pharmacological-interventions, Bronchiolitis, Asthma, Pneumonia, infants

Brief summary

The magnitude of seasonal RSV epidemics brings each year new logistical challenges for the hospitalization of young infants with bronchiolitis that overwhelm hospital capacities and lead to specific winter plans with deprogramming and mobilization of human and logistical resources. The Covid-19 pandemic has changed the way winter epidemics are presented. For example, the seasonal RSV epidemic was shifted by several months in Lyon, with an impression of a lower incidence of hospitalized cases, with a population of older children and with fewer signs of clinical severity. This is largely attributable to the widespread use of barrier gestures and social distancing measures, known as non-pharmacological interventions or NPI. Given the magnitude of the reduction of the RSV epidemic, it is legitimate to analyze the benefits of NPIs to draw lessons for maintaining preventive measures around RSV-vulnerable populations; moreover, new preventive pharmacological interventions are soon to be marketed, whether they are particularly refined and long half-life anti-RSV monoclonal antibodies, RSV vaccines for mothers or for newborns and infants. In this perspective, it is crucial to properly define the populations at risk of severe disease to establish a legitimate hierarchy in the implementation of different preventive strategies. The study of the RSV epidemic is a high potential model because of the convergence of epidemiological, virological, and pharmacological knowledge. However, the study of the impact of the pandemic on the epidemiology of rhinovirus also seems promising because, for reasons unknown to date, it seems that the pandemic did not have the same reducing impact on the rhinovirus epidemic; in the latter case, the interest is to confirm the resistance of this virus and to look for more fundamental explanations, for example, on viral interactions. On a previous study (see NTC 04944160), 519 infants and children were recruited in the Pre-Covid-19 season population, and 277 infants and children were recruited in the first Per-Covid-19 season population. In the present study, the objective is to assess the epidemiology of RVS in infants from the birth cohorts of the tertiary teaching hospitals of Lyon, France, during the Pre-Covid-19 (2013-2020) and the Per-Covid-19 (2020-2025) years.

Interventions

OTHERepidemiology

To review of medical records to describe diagnosis and severity of the disease.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 1 Years
Healthy volunteers
No

Inclusion criteria

* Child hospitalized at Hôpital Femme Mère Enfant , Lyon, France * Positive RSV-PCR

Exclusion criteria

* • Parent's refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
Annual evolution of the number and severity of RSV-infection in hospitalized children during per-Covid-19 epidemic compared to pre-Covid-19 pandemicDay 0Description of number of cases for each clinical picture according to pre-SARS-CoV-2 pandemic and per-SARS-CoV-2 pandemic year.

Countries

France

Contacts

Primary Contactdominique PLOIN, PhD
dominique.ploin@chu-lyon.fr04 27 85 56 42
Backup ContactJean-Sébastien CASALEGNO, PhD
jean-sebastien.casalegno@chu-lyon.fr: 04 72 07 10 23

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026